NCT05664217Phase 2, phase 3Terminated

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Study sponsor: Nektar Therapeutics · NKTR

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-05-22Actual
Enrollment · participants15Actual
Source updated2026-10-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Complete response (CR) rate at month 6 Description: The incidence of complete response by the Lugano Classification (Cheson et al, 2014) as determined by blinded independent central review (BICR) Time frame: At month 6 after the first infusion with study drug Measure: Event-free survival (EFS) Description: Event-free survival is defined as the time from randomization to the earliest date of disease progression by the Lugano Classification (Cheson et al, 2014) as determined by BICR, commencement of new lymphoma therapy, or death from any cause. Time frame: Up to 3 years after the first infusion with study drug. After: Measure: Complete Response (CR) Rate Description: The incidence of complete response by the Lugano Classification (Cheson et al, 2014) as determined by blinded independent central review (BICR) Time frame: At month 6.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview